ATE517638T1 - Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln - Google Patents
Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mittelnInfo
- Publication number
- ATE517638T1 ATE517638T1 AT04737253T AT04737253T ATE517638T1 AT E517638 T1 ATE517638 T1 AT E517638T1 AT 04737253 T AT04737253 T AT 04737253T AT 04737253 T AT04737253 T AT 04737253T AT E517638 T1 ATE517638 T1 AT E517638T1
- Authority
- AT
- Austria
- Prior art keywords
- preparations
- diagnostic agents
- administering therapeutic
- targeting
- therapeutic
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000000032 diagnostic agent Substances 0.000 title 1
- 229940039227 diagnostic agent Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 230000008685 targeting Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44435703P | 2003-01-31 | 2003-01-31 | |
| PCT/US2004/002768 WO2004074434A2 (en) | 2003-01-31 | 2004-02-02 | Methods and compositions for administering therapeutic and diagnostic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE517638T1 true ATE517638T1 (de) | 2011-08-15 |
Family
ID=32908405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04737253T ATE517638T1 (de) | 2003-01-31 | 2004-02-02 | Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7534431B2 (de) |
| EP (1) | EP1587550B1 (de) |
| JP (1) | JP4874090B2 (de) |
| CN (1) | CN1767860A (de) |
| AT (1) | ATE517638T1 (de) |
| AU (1) | AU2004213752B2 (de) |
| CA (1) | CA2514277C (de) |
| IL (1) | IL169896A (de) |
| MX (1) | MXPA05008222A (de) |
| WO (1) | WO2004074434A2 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405320B2 (en) * | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| US7312318B2 (en) * | 2002-03-01 | 2007-12-25 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| MXPA05008222A (es) * | 2003-01-31 | 2005-10-05 | Immunomedics Inc | Metodos y composiciones para administrar agentes terapeuticos y de diagnostico. |
| NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| US20050261170A1 (en) * | 2004-01-22 | 2005-11-24 | Immunomedics, Inc. | Folate conjugates and complexes |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| PL1874821T3 (pl) | 2005-04-26 | 2013-09-30 | Trion Pharma Gmbh | Kombinacja przeciwciał i glikokortykoidów do leczenia raka |
| US20070128116A1 (en) * | 2005-07-27 | 2007-06-07 | Wang Zheng J | Multifunctional core for molecular imaging and targeted delivery of macromolecules and drugs |
| CN101287503A (zh) * | 2005-08-03 | 2008-10-15 | Rq生物科技有限公司 | 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物 |
| US8080534B2 (en) * | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
| GB0524987D0 (en) * | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
| WO2007089871A2 (en) * | 2006-02-01 | 2007-08-09 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| WO2007134037A2 (en) * | 2006-05-15 | 2007-11-22 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
| US20080031866A1 (en) * | 2006-06-20 | 2008-02-07 | Eichenbaum Gary M | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
| WO2008034123A2 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| US20100255117A1 (en) * | 2007-04-06 | 2010-10-07 | The Johns Hopkins University | Methods and compositions for the treatment of cancer |
| RU2010107199A (ru) * | 2007-07-31 | 2011-09-10 | Дзе Джонс Хопкинс Юниверсити (Us) | Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений |
| WO2009087474A2 (en) | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| US8475763B2 (en) * | 2008-10-09 | 2013-07-02 | Actis, Ltd. | Method of determining the course of treatment for a patient having adenocarcinoma |
| US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| US8512728B2 (en) * | 2009-02-21 | 2013-08-20 | Sofradim Production | Method of forming a medical device on biological tissue |
| EP2478110B1 (de) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Klasse-i-anti-cea-antikörper und verwendungen davon |
| AU2010326004B2 (en) * | 2009-12-04 | 2016-04-21 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| US10167319B2 (en) | 2010-05-29 | 2019-01-01 | Ben-Gurion University Of Negev Research & Development Authority | Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications |
| AU2011295715B9 (en) | 2010-09-03 | 2017-02-23 | Abbvie Stemcentrx Llc | Novel modulators and methods of use |
| WO2012112317A1 (en) * | 2011-02-15 | 2012-08-23 | Albert Einstein College Of Medicine Of Yeshiva University | Radiobacteria for therapy of cancer |
| US20130231583A1 (en) * | 2012-03-02 | 2013-09-05 | Donna Rekkerth | Methods and Compositions for Injection Delivery |
| AU2013274199B2 (en) | 2012-06-14 | 2016-08-11 | Microvention, Inc. | Polymeric treatment compositions |
| MX338711B (es) | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| WO2014062696A1 (en) | 2012-10-15 | 2014-04-24 | Microvention, Inc. | Polymeric treatment compositions |
| WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| JP6064601B2 (ja) | 2013-01-09 | 2017-01-25 | オムロンヘルスケア株式会社 | 超音波式吸入器用の薬液槽および薬液パック |
| JP2016510324A (ja) * | 2013-01-17 | 2016-04-07 | シット・ソフト・インテリジェント・セラピューティクス・ゲーエムベーハー・ウント・コー・カーゲー | 選択的細胞死誘発バイナリ−酵素系 |
| JP2016513098A (ja) * | 2013-02-07 | 2016-05-12 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ） |
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| US9388243B2 (en) * | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
| JP6270264B2 (ja) * | 2014-02-04 | 2018-01-31 | 株式会社ミツトヨ | 情報処理装置、情報処理方法、プログラム、測定装置、及び測定方法 |
| CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| EP3193940A1 (de) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepine und konjugate daraus |
| AU2016252771B2 (en) | 2015-04-22 | 2021-12-16 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
| US10126298B2 (en) | 2015-05-04 | 2018-11-13 | Arman Nabatian | Hydrogels containing embedded substrates for targeted binding of molecules |
| US9687547B2 (en) | 2015-05-28 | 2017-06-27 | Immunomedics, Inc. | T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines |
| US11254744B2 (en) | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| WO2017192863A1 (en) | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| US10368874B2 (en) | 2016-08-26 | 2019-08-06 | Microvention, Inc. | Embolic compositions |
| MX2019004029A (es) | 2016-10-07 | 2019-09-27 | Navidea Biopharmaceuticals Inc | Compuestos y metodos para diagnosis y tratamiento de infecciones virales. |
| EP3525829A1 (de) | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antikörper-wirkstoffkonjugate mit immunvermittelten therapiemitteln |
| WO2018085050A1 (en) * | 2016-11-03 | 2018-05-11 | Sanford Burnham Prebys Medical Discovery Institute | Compositions and methods for imaging tissues and tumors |
| EP3375871A1 (de) | 2017-03-13 | 2018-09-19 | SIT Biotech GmbH | Enzymsystem zur auslösung von selektivem zelltod |
| US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| JP7362598B2 (ja) * | 2017-10-09 | 2023-10-17 | マイクロベンション インコーポレイテッド | 放射性液体塞栓物質 |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| EP3801217A4 (de) | 2018-05-30 | 2022-07-20 | Zap Surgical Systems, Inc. | Radiochirurgische neuromodulation in der nähe von kritischen strukturen |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4426727A2 (de) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Spezifische konjugation eines antikörpers |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3927193A (en) | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
| US4150149A (en) | 1976-11-29 | 1979-04-17 | Professional Staff Association Of The Los Angeles County Harbor General Hospital | Method and means for the early detection and diagnosis of certain types of cancers |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4468457A (en) | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
| US4460459A (en) | 1983-02-16 | 1984-07-17 | Anschutz Mining Corporation | Sequential flotation of sulfide ores |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| WO1993021940A1 (en) | 1992-05-06 | 1993-11-11 | Immunomedics, Inc. | Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy |
| US5914312A (en) * | 1992-06-09 | 1999-06-22 | Neorx Corporation | Pretargeting methods and compounds |
| EP0646019B9 (de) * | 1992-06-09 | 2002-12-18 | Neorx Corporation | Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren |
| US5846741A (en) | 1992-08-21 | 1998-12-08 | Immunomedics, Inc. | Boron neutron capture therapy using pre-targeting methods |
| US6120768A (en) | 1993-05-17 | 2000-09-19 | Immunomedics, Inc. | Dota-biotin derivatives |
| WO1995015978A1 (en) * | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| DE69534530T2 (de) * | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US5965115A (en) | 1997-11-05 | 1999-10-12 | The Procter & Gamble Company | Personal care compositions |
| US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US7074405B1 (en) | 1998-06-22 | 2006-07-11 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| ATE499115T1 (de) * | 1998-09-18 | 2011-03-15 | Immunomedics Inc | Antikörper verwiesene enzymprodrugtherapie mit glukuronidase |
| US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7312318B2 (en) * | 2002-03-01 | 2007-12-25 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| WO2003057829A2 (en) * | 2001-12-26 | 2003-07-17 | Immunomedics, Inc. | Methods of generating multispecific, multivalent agents from vh and vl domains |
| WO2003068821A2 (en) * | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| CA2478047C (en) * | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| JP2006502091A (ja) * | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
| US7597876B2 (en) * | 2007-01-11 | 2009-10-06 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| US7563433B2 (en) * | 2007-01-11 | 2009-07-21 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
| JP4083507B2 (ja) * | 2002-08-28 | 2008-04-30 | セイコーインスツル株式会社 | 半導体装置の製造方法 |
| MXPA05008222A (es) * | 2003-01-31 | 2005-10-05 | Immunomedics Inc | Metodos y composiciones para administrar agentes terapeuticos y de diagnostico. |
| US7172751B2 (en) * | 2003-06-13 | 2007-02-06 | Immunomedics, Inc. | D-amino acid peptides |
| CA2604032C (en) * | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US8153100B2 (en) * | 2007-01-11 | 2012-04-10 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
-
2004
- 2004-02-02 MX MXPA05008222A patent/MXPA05008222A/es active IP Right Grant
- 2004-02-02 CN CNA2004800090642A patent/CN1767860A/zh active Pending
- 2004-02-02 EP EP04737253A patent/EP1587550B1/de not_active Expired - Lifetime
- 2004-02-02 WO PCT/US2004/002768 patent/WO2004074434A2/en not_active Ceased
- 2004-02-02 AU AU2004213752A patent/AU2004213752B2/en not_active Ceased
- 2004-02-02 AT AT04737253T patent/ATE517638T1/de not_active IP Right Cessation
- 2004-02-02 US US10/768,707 patent/US7534431B2/en not_active Expired - Fee Related
- 2004-02-02 JP JP2006503216A patent/JP4874090B2/ja not_active Expired - Fee Related
- 2004-02-02 CA CA2514277A patent/CA2514277C/en not_active Expired - Fee Related
-
2005
- 2005-07-26 IL IL169896A patent/IL169896A/en active IP Right Grant
-
2009
- 2009-04-09 US US12/420,864 patent/US7892547B2/en not_active Expired - Fee Related
-
2011
- 2011-01-06 US US12/985,775 patent/US8097252B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7892547B2 (en) | 2011-02-22 |
| JP4874090B2 (ja) | 2012-02-08 |
| EP1587550B1 (de) | 2011-07-27 |
| WO2004074434A3 (en) | 2005-03-17 |
| US8097252B2 (en) | 2012-01-17 |
| US7534431B2 (en) | 2009-05-19 |
| WO2004074434A2 (en) | 2004-09-02 |
| EP1587550A2 (de) | 2005-10-26 |
| MXPA05008222A (es) | 2005-10-05 |
| CN1767860A (zh) | 2006-05-03 |
| IL169896A (en) | 2011-03-31 |
| AU2004213752A1 (en) | 2004-09-02 |
| US20090238757A1 (en) | 2009-09-24 |
| JP2006518737A (ja) | 2006-08-17 |
| AU2004213752B2 (en) | 2008-10-23 |
| US20040241158A1 (en) | 2004-12-02 |
| CA2514277C (en) | 2015-01-20 |
| US20110117010A1 (en) | 2011-05-19 |
| CA2514277A1 (en) | 2004-09-02 |
| IL169896A0 (en) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE517638T1 (de) | Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln | |
| SG155054A1 (en) | Human anti- neutralizing antibodies as selective pathway inhibitors | |
| ATE450251T1 (de) | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung | |
| EA201000245A1 (ru) | Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf | |
| PE20110102A1 (es) | Derivados de n-(2-oxo-2-pirrolidinil-1-il)etil-2-amino-acetamida como inhibidores de proteinas de apoptosis (iap) | |
| ATE443260T1 (de) | Kontrastmittel und verfahren zum imaging von naaldase oder psma | |
| NO20045521L (no) | Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer | |
| EA200700117A1 (ru) | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов | |
| EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
| CY1111263T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης | |
| EA200701036A1 (ru) | Лактамные соединения и их применение в качестве фармацевтических препаратов | |
| BRPI0411241A (pt) | agentes terapêuticos úteis para o tratamento de dor | |
| DE60229059D1 (de) | Proteomimetische verbindungen und verfahren | |
| ATE511645T1 (de) | Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme | |
| ATE521357T1 (de) | Verfahren zur behandlung von hepatitis | |
| CY1109868T1 (el) | Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c | |
| ATE526037T1 (de) | Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen | |
| FI20011664A7 (fi) | Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö | |
| DE60319083D1 (de) | Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug | |
| DE602005021534D1 (de) | Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung | |
| ATE497763T1 (de) | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
| ATE247130T1 (de) | Inhibitoren für den urokinaserezeptor | |
| ATE445644T1 (de) | Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |